5 / 28
Notes:
Volume10, Issue 12 (Suppl)
J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 29
conferenceseries
.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20
th
International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9
th
WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Gastric Endoscopic Submucosal Dissection (ESD) as a treatment for early neoplasia and for accurate
staging of early cancers in UK Caucasian population
M Davenport
1
, Aisha Sooltangos
1
, S McGrath
3
, J Vickers
3
, S Senapati
3
, K Akhtar
3
, R George
2
and
Yeng Ang
1
1
Salford Royal NHS Foundation Trust, UK
2
Pennine Acute NHS Trust - Salford Royal NHS foundation Trust, UK
3
Salford Royal NHS Foundation Trust, UK
Aim:
To investigate the efficacy of Endoscopic Submucosal Dissection (ESD) at diagnosing and treating superficial neoplastic
lesions of the stomach in a Caucasian population.
Methods:
Data of Caucasian patients treated with or considered for ESD at a tertiary referral center were retrieved for a
3-year period. Primary outcomes were curative resection (CR), which was defined as ESD resections with clear margins and
an absence of lymphovascular invasion, poor differentiation and submucosal involvement on histology. Secondary outcomes
were reversal of dysplasia at 12 months follow-up and/or at the latest follow up. Change in histological diagnosis pre and post
ESD was recorded.
Results:
Twenty four patients were identified with intention to treat. Nineteen patients were considered eligible, and ESD
was attempted on 25 lesions, 4 of which failed and were aborted. Out of 21 ESD performed, en-bloc resection was achieved
in 71.4% of cases. Resection was considered complete on endoscopy in 90.5% of cases compared to only 38.1% on histology.
Six resections were considered curative (28%), 5 non-curative (48%) and 10 indefinite (24%). ESD changed the histological
diagnosis in 66.6% of cases post ESD. Endoscopic follow-up in the indefinite group and CR group showed that 50% and 80% of
patients were clear of dysplasia at the latest follow-up respectively; 2 cases of recurrence were observed in the indefinite group
and survival rate for the entire cohort was 91.7%.
Conclusion:
This study provides evidence for the efficacy of ESD as a therapeutic and diagnostic intervention in Caucasian
populations and supports its application in the UK.
Biography
M Davenport is a Foundation Year 2 Doctor at Salford Royal Hospital, Manchester, UK. He is presenting on behalf of a team headed by Dr. Yeng S Ang, MD, FRCP,
Consultant Gastroenterologist, Salford Royal University Hospital, UK. Honorary Reader, University of Manchester, Manchester, UK.
Matthew.Davenport3@srft.nhs.ukM Davenport et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109